| Prev Close: | 7.61 |
|---|---|
| Open: | N/A |
| Bid: | 7.43 x 200 |
| Ask: | 9.32 x 200 |
| 1y Target Est: | 8.86 |
| Beta: | -0.86 |
| Next Earnings Date: | 7-Aug-13 |
| Day's Range: | N/A - N/A |
|---|---|
| 52wk Range: | 6.95 - 13.50 |
| Volume: | 0 |
| Avg Vol (3m): | 5,550,460 |
| Market Cap: | 1.66B |
| P/E (ttm): | N/A |
| EPS (ttm): | -0.37 |
| Div & Yield: | N/A (N/A) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Arena Pharmaceuticals CEO Presents at Wells Fargo Health Care Conference (Transcript)at Seeking Alpha(Thu, 06:33 SGT)
- Obesity Sector Gets New Shoesat Seeking Alpha(Thu, 05:01 SGT)
- It's Official: Obesity Is a Diseaseat Motley Fool(Thu, 02:41 SGT)
- AMA's Obesity-As-Disease Vote Should Boost Diet Drugsat Forbes(Wed, 19 Jun)
- 2 Biotech Approval Outcomes That Might Affect Youat Motley Fool(Wed, 19 Jun)
- Weight loss drug makers rise after AMA calls obesity a diseaseat theflyonthewall.com(Wed, 19 Jun)
- [video] Cramer's Mad Dash: Arena Pharma's Weighty Playat CNBC(Wed, 19 Jun)
- American Medical Association Decision Can Boost Arena, Vivus, And Orexigenat Seeking Alpha(Wed, 19 Jun)
- A.M.A. Recognizes Obesity as a Diseaseat New York Times(Wed, 19 Jun)
- Weight loss drug Belviq gets overdue US launchAP(Fri, 7 Jun)
- Vivus Unveils Qsymia Study ResultsZacks(Fri, 8 Feb)
- Update on Orexigen's ContraveZacks(Fri, 11 Jan)
- Takeda Terminates Amylin AgreementZacks(Mon, 31 Dec)
- Arena Cuts Loss, Affirms Sales ViewZacks(Fri, 9 Nov)
- Vivus Misses 3Q EstimatesZacks(Fri, 9 Nov)
Press Releases
- BELVIQ® (lorcaserin HCl) CIV Data to be Presented at ENDO 2013PR Newswire(Fri, 14 Jun)
- Arena Pharmaceuticals to Present at the 2013 Wells Fargo Securities Healthcare ConferencePR Newswire(Fri, 14 Jun)
- Arena Pharmaceuticals Reports on Launch of BELVIQ® (lorcaserin HCl) CIV for Chronic Weight Management in Adults who are Overweight with a Comorbidity or ObesePR Newswire(Fri, 7 Jun)